NEW YORK (GenomeWeb News) – Rosetta Genomics today said that Novitas, a designated Medicare contractor, has informed the firm that it plans to cover its miRview mets2 assay for all Medicare beneficiaries.

Rosetta's shares climbed as high as $7.84 in Wednesday trade on the Nasdaq, before closing at $4.99, up 208 percent.

The miRview mets2 test identifies tumor of origin in primary and metastatic cancer including cancer of unknown or uncertain primary.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.